Hydrogen sulfide (H 2 S), a colorless gas that is endogenously generated in mammals from cysteine, has important biological functions. Within the vasculature it regulates vessel tone and outgrowth of new vessels. This review summarizes recent literature on H 2 S signaling in the vasculature and its therapeutic potential in vascular disorders
INTRODUCTION
Hydrogen sulfide (H 2 S) is a small, water-soluble, freely permeable endogenous gasotransmitter. In humans and other mammals, H 2 S is produced by two pyridoxal-5 0 -phosphate-dependent enzymes, cystathionine-b-synthase (CBS) and cystathionineg-lyase (CSE), from the amino acid L-cysteine [1] . H 2 S is also produced from L-cysteine in an additional pathway by 3-mercaptopyruvate sulfurtransferase in combination with cysteine aminotransferase [2] .
An important physiological function of H 2 S in the vasculature is the regulation of vascular tone. CSE knockout mice show age-dependent hypertension and loss of endothelium-dependent vasorelaxation [3] . Within the vessel wall, H 2 S can be derived from both endothelial cells and vascular smooth muscle cells (VSMCs) [2] . By triggering cholinergic activity, and a subsequent increase of intracellular calcium, CSE acutely produces H 2 S in endothelial cells [3] . In VSMCs, H 2 S induces vasorelaxation partly by directly opening of potassium-ATP (K ATP ) channels [1] .
Cai et al. [4] were the first to report the proangiogenic effect of H 2 S in vitro; they demonstrated that H 2 S stimulated cell proliferation, migration and formation of tube-like structures. Since then, several groups have showed that H 2 S also acts as a proangiogenic factor in vivo [5, 6] . The proangiogenic effects of H 2 S are associated with an increase in vascular endothelial growth factor (VEGF) expression and activation of its receptor [6] .
In the current review, we will summarize more recent studies (2013-2014) on the vascular functions of H 2 S. In addition, we will give an overview of the role of H 2 S in the activation of ion channels, its proangiogenic mechanisms and the interaction between H 2 S and nitric oxide. Finally, we will discuss the possible therapeutic role of H 2 S in hypertension, ischemia-reperfusion disorders and preeclampsia.
ACTIVATION OF ION CHANNELS BY HYDROGEN SULFIDE
H 2 S is able to activate ion channels in both VSMCs and endothelial cells, as shown in Fig. 1a . In 2011, the ability of H 2 S to activate ion channels by S-sulfhydration was discovered [7] . S-sulfhydration is a covalent change of a cysteine residue, yielding a persulfide moiety (-SSH). In the Kir6.1 subunit of K ATP channels, H 2 S can sulfhydrate cysteine-43 leading to activation of the channel. Furthermore, H 2 S induces vasorelaxation via intermediate-conductance and small-conductance calcium-dependent K þ channels (IK ca and SK ca channels) in endothelial cells. It is suggested that the activation of IK ca channels by H 2 S is also due to sulfhydration [7] . Because H 2 S is able to stimulate IK ca and SK ca channels in an endothelial-dependent manner, it was speculated for years that H 2 S might act as an endothelial-derived hyperpolarization factor (EDHF). However, just a year ago, solid evidence showed that H 2 S indeed is an EDHF [8 && ]. A characteristic of an EDHF is that it is produced by endothelial cells and influences the contractility of VSMCs by inducing hyperpolarization. By using advanced techniques it was found that H 2 S yielded significant hyperpolarization in VSMCs in a dosedependent manner [8 && ]. Blocking IK ca and SK ca channels abolished this effect of H 2 S, indicating that endothelium-derived H 2 S hyperpolarizes endothelial cells via activation of these channels. Subsequently, hyperpolarization in adjacent VSMCs is induced ( Fig. 1a ) [8 && ]. Although studies are contradictory, largeconductance calcium-activated K þ channels (BK ca channels) also seem to be involved in H 2 S signaling. H 2 S inhibits BK ca channels in nonvascular cell types, whereas H 2 S-induced vasodilation of rat aortic rings is not affected by blocking BK ca channels [1, 9] . By blocking BK ca channels in rat mesenteric arteries, H 2 S-induced vasorelaxation is inhibited [10] . Recently, the same group discovered that H 2 S is able to increase intracellular calcium sparks in VSMCs [11] . Calcium sparks occur in a spatially and temporally manner when calcium is released from the endoplasmatic reticulum via RyR channels [12] . After endothelial cell disruption, or inhibition of BK ca or RyR channels, the effect of H 2 S to increase calcium sparks and induce vasorelaxation is impaired. This indicates that H 2 S increases calcium sparks in VSMCs via BK ca channels in the endothelium. Within VSMCs, calcium-sparks activate BK ca channels, which induce vasorelaxation ( Fig. 1a ) [11] . This mechanism is another way that endothelium-derived H 2 S contributes to VSMC hyperpolarization and vasodilation.
Finally, H 2 S is able to induce vasorelaxation via stimulation of K v7 voltage-gated K þ channels in VSMCs, which are important in stabilizing the membrane potential. Ex vivo the K v7 channel blocker XE991 can block H 2 S-mediated dilation of both rodent aorta and mesenteric artery [13] . More recently, it was confirmed that K v7 channels are pharmacological targets for H 2 S. In particular, the K v7.4 subunit of this channel is involved in the vasorelaxing effect of H 2 S ( Fig. 1a ) [14] .
SIGNALING PATHWAYS INVOLVED IN THE PROANGIOGENIC ACTIONS OF HYDROGEN SULFIDE
H 2 S is also a profound proangiogenic agent. Angiogenesis is a process recognized by the sprouting of new blood vessels from preexisting blood vessels. VEGF is an important mediator of angiogenesis and the majority of its biological effects are mediated by the vascular endothelial growth factor receptor 2 (VEGFR2) [15] . The ability of H 2 S or H 2 S-releasing compounds to increase VEGF production was recently confirmed by several groups [16,17,18 & ,19] . We demonstrated that exogenous administration of H 2 S increased both circulating KEY POINTS H 2 S is an endothelial-derived hyperpolarization factor.
In addition to the K ATP channels, signaling of H 2 S acts through several other ion channels such as BK ca , IK ca and SK ca channels and K v7 channels.
The main pathway involved in H 2 S-induced angiogenesis is the VEGF pathway. In addition to increasing bioavailability of VEGF, H 2 S can also directly act on its receptor.
Vasorelaxation and angiogenesis induced by H 2 S take place by both nitric oxide-dependent and nitric oxideindependent mechanisms.
Promising therapeutic strategies using several H 2 S-based therapies are currently explored for vascular diseases.
Hydrogen sulfide in vascular physiology Holwerda et al. and local (kidney) VEGF production and ameliorates hypertension and proteinuria in a rat model of 'antiangiogenic state' [19] . Agents that release H 2 S or modulate endogenous H 2 S, such as diallyl trisulfide (derived from garlic), SG-1002, and S-propargylcysteine, increase local VEGF production in animal models for ischemia [16,17,18 & ]. The mechanisms via which H 2 S influences the VEGF-signaling pathway, and consequently exerts its proangiogenic effect, are not completely understood. In 2009, it was suggested that H 2 S induces angiogenesis by stimulating K ATP channels in endothelial cells, which in turn activate MAPK pathways, inducing angiogenesis [5] . Since then, additional mechanisms have been explored, as schematically illustrated in Fig. 1b . Arrowheaded lines represent activation, bar-headed lines inhibition and dashed lines diffusion from one cell type to another. 3-MST, 3-mercaptopyruvate sulfurtransferase; BK ca, large conductance calcium-dependent potassium-channels; CBS, cystathionine-bsynthase; cGMP, cyclic guanosine monophosphate; CSE, cystathionine-g-lyase; eNOS, endothelial nitric oxide-synthase; ER, endoplasmic reticulum; H 2 S, hydrogen sulfide; IK ca, intermediate conductance calcium-dependent potassium-channels; InsP3, inositol trisphosphate; K ATP , potassium ATP-channels; K v7 , voltage-gated potassium-channel; MAPK, mitogen-activated protein kinase; PDE, phosphodiesterase; PLC, phospholipase C; SK ca , small-conductance calcium-dependent potassium-channels; SPRC, S-propargyl-cysteine; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.
that H 2 S, in its anion form HS -, is able to break the disulfide (S-S) bond between Cys1045 and Cys1024 within the VEGFR2. When a mutant form of VEGFR2 is used, which is not able to form the S-S bond, H 2 S is not able to activate the receptor and induce endothelial cell migration. Moreover, H 2 S is able to break the S-S bond and induce endothelial cell migration in the absence of VEGF protein, confirming a direct activation of the receptor by H 2 S [20 & ]. Interestingly, another group showed that H 2 S-induced vasodilation is impaired after blocking the VEGFR2 ex vivo [19] . This effect is in line with the fact that H 2 S is able to directly activate the VEGFR2. However, a positive-feedback mechanism in which the VEGFR2 stimulates H 2 S production via CSE activation is also described [21] . Subsequently, increased H 2 S in cultured endothelial cells stimulates PLC to produce InsP 3, leading to a release of intraluminal calcium and the induction of angiogenesis ( Fig. 1b) [21] .
H 2 S also promotes angiogenesis via (indirect) activation of the transcription factor STAT3, which in turn activates the VEGF promoter in the endothelial cell nucleus (Fig. 1b) [18 & ]. This mechanism was demonstrated using exogenous S-propargyl-cysteine, a compound that modulates endogenous H 2 S by inducing CSE activity. In both in-vitro and in-vivo settings, S-propargyl-cysteine promotes angiogenesis [18 & ] by increasing H 2 S, S-propargylcysteine induced phosphorylation of the transcription factor STAT3, a potential target of angiogenesismediated therapy. A direct effect of H 2 S on STAT3 was excluded, but the authors found evidence that increased H 2 S production activates the VEGFR2 that enables STAT3 to translocate to the nucleus wherein it activates downstream promoters such as the VEGF promoter ( Fig. 1b) [18 & ]. Finally, apart from upregulation of VEGF expression, data suggest that H 2 S is able to release VEGF from cells, as demonstrated in cultured podocytes [19] . The study did not unravel the mechanism through which H 2 S releases VEGF, but there are several possibilities. The ability of H 2 S to influence matrix metalloproteinases, which are known to modulate VEGF release from the inside of the cell, could be a possible mechanism. Although, studies showing the effect of H 2 S on matrix metalloproteinase-2 and matrix metalloproteinase-9 expression are conflicting [22] [23] [24] . It is unknown whether H 2 S is able to release VEGF from other cell types such as endothelial cells or VSMCs (Fig. 1b ).
THE CROSSTALK BETWEEN HYDROGEN SULFIDE AND NITRIC OXIDE
H 2 S shares structure and functions with the gasotransmitter nitric oxide, the most potent endothelium-derived relaxing factor in the vasculature. By stimulating soluble guanylyl cyclase in VSMCs, leading to increased cyclic GMP production, it subsequently induces vasorelaxation. H 2 S is able to interact with the nitric oxide-signaling pathway in several ways. For example, H 2 S promotes vasorelaxation and angiogenesis by inhibiting phosphodiesterase, an enzyme breaking down cyclic GMP [25, 26] . Furthermore, H 2 S increases nitric oxide synthase (NOS) expression in endothelial cells and stimulates the reduction from nitrite to nitric oxide in ischemic tissue [27] . Conversely, nitric oxide is able to regulate endogenous H 2 S production by increasing both CSE activity and expression [1] . It was reported that H 2 S and nitric oxide are mutually dependent in controlling vascular function [26] . However, recently it was shown in vitro that in addition to a nitric oxide-dependent mechanism, H 2 S also exerts proangiogenic functions in a nitric oxide-independent manner [28] . Moreover, it was shown that depletion of H 2 S in the kidney resulted in a reduction of nitric oxide metabolites but this was not true the other way around; reduction of H 2 S was not observed after nitric oxide depletion [29] . Therefore, a mutual dependency between the two gases appears at least to be absent in renal tissue.
One of the actions involved in the crosstalk between nitric oxide and H 2 S is phosphorylation of endothelial nitric oxide synthase (eNOS) by H 2 S [26] . This finding was confirmed in vitro by Altaany et al. [28] showing that H 2 S is able to increase eNOS phosphorylation via phosphorylation of p38 and Akt and subsequently increasing nitric oxide production. An interesting in-vivo study in 2014 evaluated this mechanism as well. Authors observed increased phosphorylation at the inhibitory site (eNOS T495 ) and decreased phosphorylation at the activating site (eNOS T1177 ) in CSE knockout mice. These alterations in eNOS phosphorylation were accompanied by reduced nitric oxide bioavailability [30 & ].
THERAPEUTIC STUDIES OF HYDROGEN SULFIDE IN VASCULAR DISORDERS
Although H 2 S has been implicated in several vascular disorders, we will focus in this section on the therapeutic studies in hypertension, acute kidney injury and preeclampsia.
Hypertension H 2 S is involved in the regulation of blood pressure. Exogenous (slow-) releasers of H 2 S such as sodium hydrosulfate (NaHS) and GYY4137 have effectively decreased blood pressure in several animal models for disease [3, 31, 32] . However, until now, no effective H 2 S-based therapies are available in the clinic. Intensive research is in progress concerning various compounds that release H 2 S or increase its endogenous production ( Table 1 ).
An interesting rediscovered compound is thiosulfate, a major H 2 S metabolite. There is evidence that thiosulfate can be an endogenous source for H 2 S signaling [33] . In the clinical setting, sodium thiosulfate is used as a therapy for calciphylaxis. Snijder et al. [34] were the first to show that sodium thiosulfate can act as a therapeutic agent in an angiotensin II-induced model for hypertension and associated hypertensive heart disease.
In the past 2 years, Martelli et al. [35] evaluated the H 2 S-releasing properties and vascular effects of arylthioamides and aryl isothiocyanates. They found that the arylthioamide p-hydroxybenzothioamide slowly released H 2 S in the presence of endogenous biomolecules such as L-cysteine. Furthermore, the arylthioamide inhibited vasoconstriction of rat aortic rings ex vivo, induced hyperpolarization in human VSMCs and lowered SBP in normotensive rats [35] . The same group showed that isothiocyanates also have vasorelaxing effects ex vivo, which is mediated via K v7 channels [36] .
Inhibitors of the angiotensin-converting enzyme (ACE) are widely used as antihypertensive drugs. It was observed that zofenopril had extra beneficial effects in patients compared with other ACE inhibitors. The beneficial effect can probably be explained by the potential of zofenopril to release H 2 S from its sulfhydryl moiety. Indeed, it was found that zofenopril had additional vascular effects, which were independently from ACE-inhibition but related to H 2 S release [37] . 
Ischemia-reperfusion and other kidney diseases
Several studies have been published on the direct renal protective effect of H 2 S, possibly independent of blood pressure (Table 1) . At first, the antioxidant role of endogenous H 2 S derived from CSE was investigated in renal ischemia reperfusion injury. CSE knockout mice suffered from increased kidney damage and mortality after renal ischemia compared with wild types, an effect that was rescued by H 2 S (administered as NaHS). Both in-vivo and in-vitro data revealed the antioxidant activity of H 2 S and its cytoprotective effect through antinecrotic mechanisms [38] . Furthermore, the compound D-cysteine was found to have a protective role in a mouse model with renal ischemiareperfusion injury [39] . Via 3MST and D-amino acid oxidase, H 2 S can be produced from D-cysteine. In the kidney, D-cysteine seems to be an important source of H 2 S. Interestingly, it was found that exogenous D-cysteine increased the renal levels of the sulfane sulphur pool, which is the major physiologically H 2 S pool. Other renal protective effects of D-cysteine, such as ameliorating renal fibrosis and glomerulosclerosis, have not been investigated so far. In a model of severe kidney damage caused by chronic infusion of angiotensin II, both H 2 S (administered as NaHS) and sodium thiosulfate attenuated hypertension, proteinuria, tubular damage and renal fibroses [40] . In another hypertensive rat model, (sFlt1-overexpression induced by adenovirus); exogenous H 2 S (using NaHS) had therapeutic effects as well [19] . Simultaneously to lowering blood pressure in this model, H 2 S reduced proteinuria and kidney damage. Indeed, the blood pressure lowering effects may be the primary mechanism of H 2 S to protect the kidney. However, we also showed that H 2 S therapy increased the expression of VEGF mRNA in the kidney [19] . As reduced local production of renal VEGF induces massive proteinuria and kidney damage [41] , H 2 S might also provide blood pressure-independent renal protection.
Preeclampsia
High circulating levels of sFlt1 are related to maternal symptoms of the gestational disease preeclampsia; a severe syndrome that is characterized by both hypertension and de-novo proteinuria in the second half of pregnancy. Placentas from preeclamptic patients show downregulation of both CBS and CSE and circulating plasma H 2 S is impaired in patients suffering from preeclampsia [42] [43] [44] . It is not surprising that H 2 S-related therapy is emerging in this field as well (Table 1) .
Within cultured human endothelial cells, knock down of CSE expression by silencing RNA resulted in increased sFlt1 and soluble endoglin (sEng), the latter is another antiangiogenic factor related to preeclampsia. Overexpression of CSE in the same cells with an adenovirus resulted in decreased sFlt1 and sEng [44] . Furthermore, in an assay wherein invitro tube formation is inhibited by both recombinant sFlt1 and preeclamptic serum, H 2 S is able to increase tube formation [19, 44] . In vivo, the effect of H 2 S on angiogenic factors was also observed [19] . After treatment with NaHS, free plasma sFlt1 levels were obviously reduced, whereas levels of free VEGF were increased [19] . Apparently, H 2 S is able to shift the angiogenic balance from antiangiogenic to proangiogenic. Furthermore, inhibiting CSE expression by using DL-propargylglycine (PAG) in pregnant mice induced a preeclampsia-like phenotype [44] . After treatment with the slow H 2 S-releaser GYY4137, the mice were rescued from the preeclampsia-like phenotype [44] . These two studies imply that H 2 S can act as a therapeutic agent in preeclampsia. CONCLUSION H 2 S is an endogenous gas with important physiological functions. Within the vasculature, main functions of H 2 S are vasodilation and promoting new vessel growth. Based on the discussed in-vitro and in-vivo rodent data, H 2 S is aligned to have therapeutic potential in diseases such as hypertension, renal ischemia-reperfusion disorders and hypertension. Therefore, several compounds such as the H 2 S-donor NaHS, synthetic slow releasers such as aryl isothiocyanates, arylthioamides and GYY4137, and also clinical available compounds such STS and zofenopril, are in the running to become H 2 S-based therapies for vascular disease.
